Lusvertikimab | 芦维奇单抗 _ MedChemExpress (MCE)

参考详情：Lusvertikimab (OSE-127，芦维奇单抗) - 仅供科研 | IL7R抗体 | MCE

MCE 国际站：Lusvertikimab

中文名：芦维奇单抗

CAS：2375835-91-7

品牌：MedChemExpress (MCE)

存储条件：Please store the product under the recommended conditions in the Certificate of Analysis.

生物活性：Lusvertikimab (OSE-127) 是一种人源化 IL7R 单克隆抗体。Lusvertikimab 不会被靶细胞内化并阻止 IL7R 异二聚化和随后的下游信号传导。Lusvertikimab 具有抗白血病功效，具有用于 B 细胞前体急性淋巴细胞白血病 (BCP-ALL) 研究的潜力。

体外：OSE-127 (4 天) 可阻断 IL7 依赖性 ALL 细胞系和患者来源的异种移植 (PDX) 样本中的 STAT5 磷酸化[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内：当相应的对照小鼠显示出明显白血病的临床症状时，OSE-127 处理的小鼠体内 21/22 (95%) PDX 样本显示外周血 (PB) 母细胞减少[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Clinical Trial

热销产品：Leukotriene E4-d5  | PD158780  | Veratric acid  | NVS-SM2  | PA-9  | Cy2  | Gossypol (acetic acid)  | C-021  | Cichoriin  | Purpurin

研究领域：Immunology/Inflammation

作用靶点：Interleukin Related

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

参考文献：

[1]. Lennart Lenk, et al. The IL7R-Antagonist OSE-127 Blocks Acute Lymphoblastic Leukemia Development Via a Dual Mode of Action. ACUTE LYMPHOBLASTIC LEUKEMIAS: BIOMARKERS, MOLECULAR MARKERS AND MINIMAL RESIDUAL DISEASE IN DIAGNOSIS AND PROGNOSIS| NOVEMBER 15, 2022.[2]. Elodie Rivière,, et al. Interleukin-7/Interferon Axis Drives T Cell and Salivary Gland Epithelial Cell Interactions in Sjögren's Syndrome. Arthritis Rheumatol. 2021 Apr;73(4):631-640.